To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Biolex Therapeutics is a biotechnology firm in the Research Triangle of North Carolina. The company focuses on formation of difficult to synthesize proteins in Lemna, a duckweed. The duckweeds are a family of small aquatic plants that can be grown in sterile culture. Biolex has developed recombinant DNA technology for efficiently producing pharmaceutical proteins in Lemna. Therapeutic glycosylated proteins, such as monoclonal antibodies, have been produced by the Lemna system at Biolex.
Additional recommended knowledge
Biolex acquired Epicyte Pharmaceutical Inc. on May 6, 2004, and acquired LemnaGene SA of Lyon, France in 2005. Biolex is a privately held company backed by Quaker BioVentures, The Trelys Funds, and Polaris Venture Partners. The term "plantibody" is trademarked by Biolex.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Biolex". A list of authors is available in Wikipedia.|